In Office Growth Capitalize on Urgent PC's office-based, non-drug, non-surgical modality to attract urology and urogynecology clinics seeking patient-friendly alternatives to surgery and to expand their service mix for Overactive Bladder. Emphasize FDA clearance and the ability to deliver treatment without anesthesia or operating room time, enabling higher patient throughput and recurring device utilization. Explore cross-sell opportunities with Macroplastique for appropriate SUI patients within the same practice.

International Expansion Leverage non-US indications of Macroplastique for male and female stress urinary incontinence and non-US indications for Urgent PC (fecal incontinence) to drive international growth. Target regulatory approvals, local distributors, and multi-site clinics in Europe, Asia-Pacific, and other regions to widen addressable market and increase revenue opportunities.

Low Risk Appeal Position Uroplasty products as low-risk, cost-effective alternatives to invasive surgeries, appealing to providers focused on patient safety, faster treatment cycles, and improved practice efficiency. Highlight outpatient delivery and potential for higher patient acceptance and clinic capacity.

Multi-Specialty Training Invest in provider training, education materials, and CE-accredited courses to accelerate adoption among specialists. Comprehensive onboarding reduces learning curve and supports sustained usage across OAB and SUI indications, enabling clinics to expand the range of patients treated.

Strategic Partnerships Pursue partnerships with medical distributors and multi-site practice groups to scale access to Urgent PC and Macroplastique. Align with partners that serve urogynecology, urology, and pelvic floor care to broaden footprint faster than solo sales and to compete more effectively against larger OEMs.